Adefovir Dipivoxil and Lamivudine Treatment for Decompensated Cirrhosis Influence

Objective:To investigate the treatment of adefovir dipivoxil combined with lamivudine of hepatitis B with compensated liver cirrhosis the clinical effects.Methods:From January 2009 to January 2011,65 cases of decompensated liver cirrhosis serum HBV-DNA positive patients were randomly divided into two groups.Based on the combined treatment,the observation of 33 patients was given adefovir dipivoxil and lamivudine combination therapy.In the control group,32 patients only received adefovir dipivoxil treatment.Observed treatment before and after treatment 12,24,48th weeks quantitative liver function and HBV-DNA.Results:In the 48th weeks ALT group observed recovery was 81.8%,was significantly higher than 56.3%;the observation group of serum HBV-DNA replication to improve the situation was significantly better than the control group.Difference between the two groups were statistically significant(P0.05);treatment was not found with taking adefovir dipivoxil-related adverse reactions.Conclusion:Adefovir dipivoxil and lamivudine antiviral therapy can effectively inhibit the hepatitis B virus replication,significantly control the disease progression and improve prognosis,is worthy of clinical application.